Moreover, increased SGOL1 expression was strongly associated with adverse clinical pathological characteristics, including advanced cancer stage, increased lymphatic metastasis, and increased tumor grade, and predicted worse clinical survival (OS, DSS, PFI) in ccRCC patients. Here, SGO1 is linked to neoplasm.